Epigenetic therapy in allogeneic hematopoietic stem cell transplantation

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Epigenetic alterations, including DNA methylation, are implicated in cancer development.
• DNA methyltransferases (DNMTs) regulate gene expression by methylating CpG islands, potentially silencing tumor suppressor genes.
• DNMT inhibitors, such as azacitidine and decitabine, exhibit anti-tumor activity and immunomodulatory effects.

Purpose of the Study:

• To review the emerging role of epigenetic manipulation with hypomethylating agents in allogeneic stem cell transplantation.
• To explore the potential of these agents in enhancing graft-versus-leukemia (GVL) effects and mitigating graft-versus-host disease (GVHD).

Main Methods:

• Literature review of studies investigating hypomethylating agents in allogeneic transplantation.
• Analysis of data on the perioperative use of azacitidine and decitabine.
• Examination of hypotheses regarding low-dose azacitidine's impact on GVL and GVHD.

Main Results:

• Azacitidine and decitabine have demonstrated anti-tumor activity in various malignancies, particularly myelodysplastic syndromes.
• These agents have shown immunomodulatory effects relevant to allogeneic stem cell transplantation.
• Perioperative use of these drugs has yielded variable success rates.

Conclusions:

• Hypomethylating agents represent a rapidly advancing area in epigenetic manipulation for allogeneic transplantation.
• Low-dose azacitidine may potentially enhance the GVL effect and aid in remission maintenance for myeloid leukemias.
• There is intriguing potential for these agents to improve transplant outcomes by modulating both GVL and GVHD.